All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drtoddstrong on TikTok · 158s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drtoddstrong's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00H.P.L.R.E. The silent gut infection affecting over half the world and why treating it wrong
  2. 0:05makes it worse. H.P.L.R.E. is a bacterial infection that lives in your stomach lining.
  3. 0:10Over 50% of the world's population carries it. It destroys your stomach acid, causing
  4. 0:15ulcers, driving chronic inflammation and blocks B12 absorption, and has now been linked to
  5. 0:21autoimmune disease and peripheral enropathy. And most people who have it are either undiagnosed
  6. 0:27or have been treated with antibiotics that didn't fully clear it. H.P.L.R.E. survives
  7. 0:33bot neutralizing your stomach acid. It produces an enzyme called urease that converts urea
  8. 0:38into ammonia which raises the pH in your stomach and creates an environment where the bacteria
  9. 0:44can live without being destroyed. Here's why that matters for everything downstream.
  10. 0:50Low stomach acid means proteins don't get broken down properly. Undotjusted proteins
  11. 0:55cross into the bloodstream through a leaky gut lining and trigger immune reactivity. The
  12. 1:01foundation of autoimmune disease. Low stomach acid means B12 can't be absorbed. B12 deficiency
  13. 1:08is one of the most direct drivers of peripheral enropathy. And chronic H.P.L.R.E. infection
  14. 1:14keeps the stomach lining inflamed indefinitely. Perpetuating the gut dysfunction that drives
  15. 1:20every chronic condition a treat. H.P.L.R.E. forms what's called a biofilm, a protective
  16. 1:25coating that shields it from antibiotics. Standard triple therapy clears it in about 70 to 80%
  17. 1:31of cases. The remaining 20 to 30% have a biofilm protected infection that the antibiotic simply
  18. 1:37cannot penetrate. If you've done two rounds of antibiotics and still test positive or
  19. 1:42still have symptoms, biofilm disruption is the missing step. This requires specific
  20. 1:48enzymes like seropipidase or enocetal cysteine taken before the antimicrobial protocol to break
  21. 1:54down the shield down first. Mastic gum in 1000 milligrams twice daily has clinical data showing
  22. 2:00it kills H.P.L.R.E. including antibiotic resistant strains. Zincarnicine repairs the stomach lining
  23. 2:06simultaneously and DGL licorice soothes inflammation while the infection clears. These aren't replacements
  24. 2:12for treatment. They're the pieces the antibiotic protocol left out. Have you been tested for
  25. 2:18H.P.L.R.E. or are you on your second round of antibiotics and still struggling? Drop
  26. 2:23your situation in the comments below. This is one of the most treatable root causes I
  27. 2:27work with. When it's approached correctly, everything I use with my patients is in the free master
  28. 2:34class. The link is in my profile. Go check it out.

H. pylori and gut health claims: what TikTok gets wrong

Dr. Strong

TikTok creator

31.1K viewsWatch on TikTok

Quick answer

H. pylori eradication failure is a genuine clinical problem, with antibiotic resistance rates rising globally and second-line therapy often requiring bismuth quadruple regimens per ACG guidelines. The creator's focus on biofilm protection as an explanation for treatment failure has some mechanistic support but lacks robust human trial data for the specific enzyme-based disruption strategy he recommends. Patients who have failed two antibiotic courses should pursue culture-guided susceptibility testing or specialist referral, not solely adjunct supplement protocols.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For H. pylori and gut health claims: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

H. pylori and gut health claims: what TikTok gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "H. pylori and gut health claims: what TikTok gets wrong" from Dr. Strong. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: H.

The reason this review is not generic is the source wording and the canonical claim label "peptides h pylori the silent gut infection affecting over half the wo." In this clip, the useful excerpt is: "H." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Emerging pharmacotherapies for obesity: A systematic review (2025), Glucagon-like receptor agonists and next-generation incretin-based medications (2026), and Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Standard triple therapy failure rates of 20-30% are supported by current literature, including Malfertheiner et al.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

H.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • H. pylori eradication failure is a genuine clinical problem, with antibiotic resistance rates rising globally and second-line therapy often requiring bismuth quadruple regimens per ACG guidelines. The creator's focus on biofilm protection as an explanation for treatment failure has some mechanistic support but lacks robust human trial data for the specific enzyme-based disruption strategy he recommends. Patients who have failed two antibiotic courses should pursue culture-guided susceptibility testing or specialist referral, not solely adjunct supplement protocols.
  • Over 50% of the global population carries H. pylori, and the WHO classifies it as a Group 1 carcinogen for gastric cancer, making awareness genuinely important.
  • Standard triple therapy failure rates of 20-30% are supported by current literature, including Malfertheiner et al. (2022, Gut), and second-line bismuth quadruple therapy is the ACG-recommended next step, not a repeat of the same regimen.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Over 50% of the global population carries H. pylori, and the WHO classifies it as a Group 1 carcinogen for gastric cancer, making awareness genuinely important.
  • Standard triple therapy failure rates of 20-30% are supported by current literature, including Malfertheiner et al. (2022, Gut), and second-line bismuth quadruple therapy is the ACG-recommended next step, not a repeat of the same regimen.
  • H. pylori biofilm formation is documented in laboratory settings, but no randomized controlled trial has confirmed that taking oral serrapeptase or NAC before antibiotics improves eradication rates in humans.
  • Mastic gum has small-scale clinical evidence for H. pylori activity (Dabos et al., 2010, Phytomedicine), but it is not a clinically validated replacement for antibiotic therapy and should not be used as one.
  • Zinc carnosine has evidence for gastric mucosal protection and repair (Mahmood et al., 2007, Journal of Nutritional Biochemistry) and is a reasonable adjunct, though it does not treat the infection itself.
  • If you have failed two antibiotic rounds and still test positive, the appropriate step is culture-guided susceptibility testing with a gastroenterologist, not a supplement protocol from a social media masterclass.
  • The connection between H. pylori, B12 deficiency, and peripheral neuropathy is mechanistically plausible and has some clinical backing, but the jump to broad autoimmune causation is not supported by current evidence.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drtoddstrong actually say?

The core argument here is that H. pylori is chronically undertreated because standard antibiotic triple therapy fails in 20-30% of cases due to biofilm protection, and that specific natural compounds can fill the gap. He names mastic gum at "1000 milligrams twice daily," serrapeptase and N-acetyl cysteine as biofilm disruptors, and zinc carnosine plus DGL licorice as repair agents. He also connects untreated H. pylori to leaky gut, autoimmune disease, B12 deficiency, and peripheral neuropathy, framing these as a mechanistic chain his patients regularly respond to.

He's selling a free masterclass at the end, which is worth noting. That doesn't automatically make his claims wrong, but it does mean the framing is designed to move people toward his protocol, not just inform them.

Does the science back this up?

Partially, and more than you might expect from a TikTok peptide account. The antibiotic failure rate figure is accurate. The biofilm concern is real but more contested than he implies. The mastic gum claim has actual evidence behind it, though modest. The autoimmune and neuropathy links are supported but presented with more certainty than the literature warrants.

H. pylori eradication with standard triple therapy (a proton pump inhibitor plus two antibiotics) achieves roughly 70-85% success in clinical practice, though rates vary significantly by region and clarithromycin resistance patterns (Malfertheiner et al., 2022, Gut). That matches his stated range. Biofilm formation by H. pylori has been documented in vitro and in some clinical samples (Carron et al., 2006, Journal of Gastroenterology and Hepatology), though whether biofilm disruption with oral enzymes meaningfully improves clearance in humans is not yet established by randomized trials. Mastic gum does show antimicrobial activity against H. pylori in vitro and in small clinical studies (Huwez et al., 1998, New England Journal of Medicine correspondence; Dabos et al., 2010, Phytomedicine), including against some resistant strains. The effect sizes are modest and the evidence base is thin. It is not a substitute for antibiotics in most cases.

What did they get wrong or right?

He got the mechanism of urease production and stomach acid neutralization right. That is textbook H. pylori physiology (Marshall and Warren, 1984, Lancet). The downstream logic connecting low stomach acid to impaired protein digestion and B12 malabsorption is also grounded. B12 requires intrinsic factor and adequate gastric acid for absorption, and H. pylori gastritis does impair this (Kaptan et al., 2000, Archives of Internal Medicine).

Where he overreaches is on the autoimmune connection. The link between H. pylori and autoimmune conditions is an active research area with some evidence for specific conditions like immune thrombocytopenic purpura, but framing it as "the foundation of autoimmune disease" is a significant overclaim. The leaky gut mechanism he describes, undigested proteins crossing the gut lining and triggering immune reactivity, is a plausible hypothesis, not an established causal chain. He presents it as settled science, and it is not.

The dosing recommendation of mastic gum at 1000 mg twice daily mirrors what was used in Dabos et al. 2010. Repeating a study dose is different from prescribing, but it is still something to flag: this article does not endorse that dose, and readers should consult a provider.

What should you actually know?

H. pylori is genuinely one of the most common chronic bacterial infections on earth, and the WHO classifies it as a Group 1 carcinogen for gastric cancer. Getting tested if you have persistent GI symptoms, unexplained B12 deficiency, or a history of ulcers is reasonable and evidence-backed. A urea breath test or stool antigen test are the standard non-invasive diagnostics.

If you have failed one antibiotic course, the clinical recommendation is not to just try again with the same regimen. Quadruple therapy or bismuth-based regimens are recommended as second-line treatment by the American College of Gastroenterology. The biofilm disruption protocol he describes, using serrapeptase or NAC before antibiotics, has biological plausibility but lacks clinical trial evidence in humans. Mastic gum may be a useful adjunct but is not a replacement for medical treatment. Zinc carnosine has good evidence for gastric mucosal repair (Mahmood et al., 2007, Journal of Nutritional Biochemistry). None of these are regulated as drugs in the US. If you are on a second round of antibiotics and still testing positive, that conversation belongs with a gastroenterologist, not a TikTok masterclass.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Strong · TikTok creator

31.1K views on this video

H. Pylori: The Silent Gut Infection Affecting Over Half the World — And Why Treating It Wrong Makes It Worse #leakygut #gut #autoimmune #hpylori #guthealth

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about over 50% of the global population carries h. pylori,?

Over 50% of the global population carries H. pylori, and the WHO classifies it as a Group 1 carcinogen for gastric cancer, making awareness genuinely important.

What does the video say about standard triple therapy failure rates of 20-30%?

Standard triple therapy failure rates of 20-30% are supported by current literature, including Malfertheiner et al. (2022, Gut), and second-line bismuth quadruple therapy is the ACG-recommended next step, not a repeat of the same regimen.

What does the video say about h. pylori biofilm formation?

H. pylori biofilm formation is documented in laboratory settings, but no randomized controlled trial has confirmed that taking oral serrapeptase or NAC before antibiotics improves eradication rates in humans.

What does the video say about mastic gum has small-scale clinical evidence for h. pylori activity?

Mastic gum has small-scale clinical evidence for H. pylori activity (Dabos et al., 2010, Phytomedicine), but it is not a clinically validated replacement for antibiotic therapy and should not be used as one.

What does the video say about zinc carnosine has evidence for gastric mucosal protection?

Zinc carnosine has evidence for gastric mucosal protection and repair (Mahmood et al., 2007, Journal of Nutritional Biochemistry) and is a reasonable adjunct, though it does not treat the infection itself.

What does the video say about if you have failed two antibiotic rounds?

If you have failed two antibiotic rounds and still test positive, the appropriate step is culture-guided susceptibility testing with a gastroenterologist, not a supplement protocol from a social media masterclass.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Strong, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.